BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mellgren K, Nierop AF, Abrahamsson J. Use of Multivariate Immune Reconstitution Patterns to Describe Immune Reconstitution after Allogeneic Stem Cell Transplantation in Children. Biology of Blood and Marrow Transplantation 2019;25:2045-53. [DOI: 10.1016/j.bbmt.2019.06.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Giver CR. Antiviral Immune Monitoring and Support in Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2020;26:e92-3. [PMID: 32188575 DOI: 10.1016/j.bbmt.2020.03.010] [Reference Citation Analysis]
2 Yanir A, Schulz A, Lawitschka A, Nierkens S, Eyrich M. Immune Reconstitution After Allogeneic Haematopoietic Cell Transplantation: From Observational Studies to Targeted Interventions. Front Pediatr 2022;9:786017. [DOI: 10.3389/fped.2021.786017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Diana J, Bouazza N, Couzin C, Castelle M, Magnani A, Magrin E, Rosain J, Treluyer J, Picard C, Moshous D, Blanche S, Neven B, Cavazzana M. Bayesian Modeling Immune Reconstitution Apply to CD34+ Selected Stem Cell Transplantation for Severe Combined Immunodeficiency. Front Pediatr 2022;9:804912. [DOI: 10.3389/fped.2021.804912] [Reference Citation Analysis]
4 Li Y, Wang M, Fang X, Jiang Y, Sui X, Li Y, Liu X, Wang X, Lu D, Sun X, Xu H, Wang X. The impact of different doses of antithymocyte globulin conditioning on immune reconstitution upon hematopoietic stem cell transplantation. Transpl Immunol 2021;69:101486. [PMID: 34678462 DOI: 10.1016/j.trim.2021.101486] [Reference Citation Analysis]
5 Hayashi RJ. Considerations in Preparative Regimen Selection to Minimize Rejection in Pediatric Hematopoietic Transplantation in Non-Malignant Diseases. Front Immunol 2020;11:567423. [PMID: 33193340 DOI: 10.3389/fimmu.2020.567423] [Reference Citation Analysis]
6 Spyridonidis A. How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation. Blood 2020;135:1639-49. [PMID: 31961921 DOI: 10.1182/blood.2019003566] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
7 Spadea M, Saglio F, Tripodi SI, Menconi M, Zecca M, Fagioli F. Multivariate Analysis of Immune Reconstitution and Relapse Risk Scoring in Children Receiving Allogeneic Stem Cell Transplantation for Acute Leukemias. Transplant Direct 2021;7:e774. [PMID: 34646937 DOI: 10.1097/TXD.0000000000001226] [Reference Citation Analysis]
8 Bhatt ST, Bednarski JJ. Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders. Front Immunol 2020;11:1988. [PMID: 33013851 DOI: 10.3389/fimmu.2020.01988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]